Reports

Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.
Download Report
Originally published on 10/11/2019 Drug Pricing Lab

Recent federal policy proposals, including H.R. 3 Lower Drug Costs Now Act of 2019, link Medicare payments for prescription drugs to prices paid in other countries. International price reference proposals are met with industry critique that this would inhibit patient access to drugs in the U.S. where the FDA process is faster and more comprehensive.

In this Drug Pricing Lab policy paper, we present a review of the literature and a more robust explanation that includes factors that contribute to company filing decisions such as country revenue and pricing potential. Implementing international reference pricing based on prices paid for in other high-income countries is unlikely to change the U.S.'s position as the leading country in drug pricing and revenue opportunity.

Read the full policy paper here.

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

DPL Responds to HHS RFI for IPI Drug Pricing Model…
Our response to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs.
Drug Pricing Lab 12/31/2018
The Conflict Between QALYs and Well-Funded Patient Advocacy Groups
The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.
Relentless Health Value 12/10/2020
Remdesivir Less Expensive for "Government Programs"? Not So Fast.
Two options are proposed if Gilead wishes to offer the discounts to the full array of government programs.
Drug Pricing Lab 07/01/2020
Blueprints for Indication-Specific Pricing
Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.
Drug Pricing Lab 05/19/2020
Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Drop in Cancer Deaths Reflect Failures of Our Society. Really.
Despite declining cancer death rates, the nation still presents societal failures to improve the state of our population's health.
The Boston Globe 02/21/2020
Dissecting PhRMA's Opposition to H.R. 3 Lower Drug Costs Now…
Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.
STAT News 10/11/2019
Time to Throw in the Towel on Biosimilars
Peter Bach and Mark Trusheim of MIT Sloan School of Management underscore the drawbacks of Washington's preferred solution to introduce competition for biologics, the biosimilar model.
The Wall Street Journal 08/21/2019
Mortgaging New Treatments Kicks the Can on High Drug Prices
The launch price for one-time gene therapy Zolgensma presents various implications.
Morning Consult 07/09/2019
A $475,000 price tag for a new cancer drug: crazy…
Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.
STAT News 08/31/2017
US Drug Prices And R&D, Take 2: A Reply To…
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Health Affairs Blog 07/27/2017
Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies
The prevalence of off-label anticancer drug use is not well characterized.
JCO 02/19/2013

Featured News

See All News
The New York Times 10/19/2015

To Reduce the Cost of Drugs, Look to Europe

When anyone proposes reducing prescription drug prices— as Hillary Rodham Clinton and Bernie Sanders recently have—the most commonly heard criticism is that it would squelch innovation.
Read Article
Newsletter

Stay up to date on our work and news